drugset / Trial / NCT05180799
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Timeline
- Start
- 2022-08-03
- Primary completion
- 2025-03-19
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evalstotug | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemetrexed | Small molecule | — | — |